LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial

• Published in: Cardiovascular diabetology 2016-02, Vol.15 (1), p.29, Article 29
• Main Authors: Masmiquel, L, Leiter, L A, Vidal, J, Bain, S, Petrie, J, Franek, E, Raz, I, Comlekci, A, Jacob, S, van Gaal, L, Baeres, F M M, Marso, S P, Eriksson, M
• Format: Article
• Language: English
• Subjects: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular diseases; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - prevention & control; Diabetes; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Diabetis; Double-Blind Method; Factors de risc en les malalties; Female; Humans; Hypoglycemic Agents - therapeutic use; Liraglutide - therapeutic use; Malalties cardiovasculars; Male; Metabolic Syndrome - diagnosis; Metabolic Syndrome - drug therapy; Metabolic Syndrome - epidemiology; Middle Aged; Obesitat; Obesity; Obesity - diagnosis; Obesity - epidemiology; Obesity - therapy; Original Investigation; Prevalence; Risk Assessment; Risk Factors; Risk factors in diseases; Time Factors; Treatment Outcome; Waist Circumference
• ISSN: 1475-2840; 1475-2840
• DOI: 10.1186/s12933-016-0341-5

Epidemiological data on obesity are needed, particularly in patients with type 2 diabetes mellitus (T2DM) and high cardiovascular (CV) risk. We used the baseline data of liraglutide effect and action in diabetes: evaluation of CV outcome results-A long term Evaluation (LEADER) (a clinical trial to assess the CV safety of liraglutide) to investigate: (i) prevalence of overweight and obesity; (ii) relationship of the major cardiometabolic risk factors with anthropometric measures of adiposity [body mass index (BMI) and waist circumference (WC)]; and (iii) cardiometabolic treatment intensity in relation to BMI and WC. LEADER enrolled two distinct populations of high-risk patients with T2DM in 32 countries: (1) aged ≥50 years with prior CV disease; (2) aged ≥60 years with one or more CV risk factors. Associations of metabolic variables, demographic variables and treatment intensity with anthropometric measurements (BMI and WC) were explored using regression models (ClinicalTrials.gov identifier: NCT01179048). Mean BMI was 32.5 ± 6.3 kg/m(2) and only 9.1 % had BMI